Orion PharmaDHA:ORIONPHARM +1.41%69 Market Cap is BDT6,739 Mil as of Jun. 28, 2026. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 69/100 and a GF Value™ of BDT20.38 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 484 Utilities - Independent Power Producers companies, Orion Pharma ranks worse than 67.77% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Orion Pharma's share price for the quarter that ended in Mar. 2026 was BDT28.8. Orion Pharma's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 234 Mil. Therefore, Orion Pharma's market cap for the quarter that ended in Mar. 2026 was BDT6,739 Mil.
Orion Pharma's quarterly market cap
declined
from Sep. 2025 (BDT8,611 Mil) to Dec. 2025 (BDT6,412 Mil) but then
increased
from Dec. 2025 (BDT6,412 Mil) to Mar. 2026 (BDT6,739 Mil).
Orion Pharma's annual market cap
declined
from Jun. 2023 (BDT18,626 Mil) to Jun. 2024 (BDT16,169 Mil) and
declined
from Jun. 2024 (BDT16,169 Mil) to Jun. 2025 (BDT7,090 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Orion Pharma's Enterprise Value for Today is BDT35,064 Mil.
Orion Pharma (DHA:ORIONPHARM) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Orion Pharma Market Cap Related Terms
Orion Pharma Market Cap Historical Data
* Premium members only.
The historical data trend for Orion Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONPHARM vs CEG, VST, NRG: Market Cap Comparison
For the Utilities - Independent Power Producers subindustry, Orion Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Pharma Market Cap vs Utilities - Independent Power Producers Industry
For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Orion Pharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Orion Pharma's Market Cap for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Pharma (DHA:ORIONPHARM) has a Market Cap of BDT6,739 Mil as of Jun. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Orion Pharma and its competitors. According to the industry distribution chart, Orion Pharma ranks #328 out of 484 companies in the Utilities - Independent Power Producers industry, placing it in the top 67.8%.
Is Orion Pharma's Market Cap too high?
Orion Pharma's current Market Cap is BDT6,739 Mil. Based on the distribution chart, Orion Pharma ranks #328 out of 484 companies in the Utilities - Independent Power Producers industry, which is below the industry midpoint. Overall, Orion Pharma has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Market Cap compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #328 out of 484 companies for Market Cap. This places Orion Pharma in the lower half of its industry. The industry median Market Cap is 204.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for an Utilities - Independent Power Producers company?
The median Market Cap among Utilities - Independent Power Producers companies is 204.57, based on 484 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Orion Pharma and its competitors. For the Utilities - Independent Power Producers industry, the median Market Cap is 204.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Pharma's current Market Cap is BDT6,739 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.38, compared to a current price of BDT28.80 — trading 41.3% above its estimated fair value. The current Market Cap is BDT6,739 Mil. Orion Pharma's overall GF Score™ is 69/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Market Cap is BDT6,739 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT28.80 is trading 41.3% above its estimated GF Value™ of BDT20.38.
GuruFocus considers Orion Pharma to be Significantly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
Market Cap: BDT6,739 Mil
GF Value™: BDT20.38 vs. price of BDT28.80 (41.3% above fair value)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
69GF Score
Get the complete analysis for DHA:ORIONPHARM
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
